中药治疗胃食管反流病的疗效与安全性:随机对照试验的系统评价与成分网络Meta分析
该系统评价与网络Meta分析纳入20项RCT共2246例GERD患者,比较中药与PPI。结果显示中药在临床疗效(OR 4.13,95%CI 2.73-6.25)和症状缓解(SMD 0.71,95%CI 0.49-0.94)上优于PPI,复发率更低且安全性相当。成分分析识别半夏为高连接度核心药物。
要点
- 中药治疗GERD在临床疗效和症状缓解上优于PPI,复发率更低且安全性相当。
- 成分网络分析识别半夏为高连接度核心药物,支持多靶点中药策略。
- 结果支持中药辅助增强食管胃屏障、减少长期PPI依赖的潜力。
核心结论
- 中药在GERD临床疗效和症状缓解上优于PPI,复发率更低且安全性相当。
- 成分层面分析支持中药多靶点策略及减少长期PPI依赖的潜力。
研究设计与样本
- 系统评价与网络Meta分析,检索英文和中文数据库至2026年4月15日。
- 纳入20项比较中药与西药的RCT,共2246例GERD患者。
- 采用RevMan 5.4进行Meta分析,Cochrane RoB 2评估偏倚风险。
- 基于成分网络Meta分析框架和核心模式网络分析进行成分贡献分析。
主要发现
- 中药在临床疗效上优于PPI(OR 4.13,95%CI 2.73-6.25)。
- 中药在症状缓解上优于PPI(SMD 0.71,95%CI 0.49-0.94)。
- 中药复发率更低且安全性相当。
- 网络Meta分析识别出多个相对PPI效果良好的中药方剂。
- 核心模式分析识别半夏为高连接度药物。
关键数值与推荐
- 临床疗效:OR 4.13,95%CI 2.73-6.25,中药优于PPI。
- 症状缓解:SMD 0.71,95%CI 0.49-0.94,中药优于PPI。
- 复发率更低、安全性相当(原文未报告具体数值)。
临床怎么用
- 可考虑中药作为GERD治疗选择以改善疗效和减少复发。
- 中药多靶点策略或有助于增强食管胃屏障、减少长期PPI依赖。
- 组方时可参考半夏等高连接度核心药物。
局限性
- 纳入研究数量有限(20项RCT),样本量2246例。
- 原文未报告具体复发率数值及安全性详细数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gastroesophageal reflux disease (GERD) is commonly treated with proton pump inhibitors (PPIs) despite their adverse effects and risk of recurrence. Chinese herbal medicine (CHM) has long been used to alleviate reflux-related symptoms and reduce relapse through multi-component and multi-target strategies. To evaluate the efficacy and safety of CHM for GERD and identify key botanical drugs contributing to therapeutic effects using a component-level analytical framework. METHODS: English and Chinese databases were screened for relevant articles up to 15 April 2026. Eligible randomized controlled trials (RCTs) compared CHM with biomedicine. A meta-analysis was performed using RevMan 5.4 software, and the risk of bias assessed using Cochrane Risk of Bias two tool. A component-level contribution analysis based on component network meta-analysis (CNMA) framework and core-pattern network analysis were used to quantify individual botanical drug contributions and co-prescription structures. RESULTS: Twenty randomized controlled trials involving 2,246 patients with GERD were included. Pairwise meta-analysis showed that CHM was superior to PPIs in clinical efficacy (odds ratio: 4.13, 95% confidence interval: 2.73-6.25) and symptom relief (standard mean difference: 0.71, 95% confidence interval: 0.49-0.94), with lower recurrence rates and equivalent safety. Network meta-analyses identified several CHM formulas with favorable effects relative to PPIs. Component-level contribution analyses identified varying associations among botanical drugs. Core-pattern analysis identified Pinelliae rhizoma as a highly connected botanical drug. CONCLUSION: This study presents the first component-level analysis of CHM prescriptions for GERD, suggesting improvements in clinical efficacy and recurrence control. By integrating prescription patterns with evidence-based pharmacology, our findings provide insights into multi-target CHM strategies and support the potential of CHM to strengthen the esophagogastric barrier and reduce long-term PPI dependence. TRIAL REGISTRATION: The study was registered on PROSPERO, registration number CRD42024612778.
引用
- Chen YT, Tai YH, Huang PY, et al. Treatment effects and safety of Chinese herbal medicine in gastroesophageal reflux disease: a systematic review of randomized controlled trials and a network meta-analysis with component analysis. Front Pharmacol. 2026. PMID: 42851651. doi:10.3389/fphar.2026.1920738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。